These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548 [TBL] [Abstract][Full Text] [Related]
5. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells. Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684 [TBL] [Abstract][Full Text] [Related]
6. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. Singh RK; Gaikwad SM; Jinager A; Chaudhury S; Maheshwari A; Ray P Cancer Lett; 2014 Nov; 354(2):254-62. PubMed ID: 25157649 [TBL] [Abstract][Full Text] [Related]
7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
8. In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer. Chen Y; Ruben EA; Rajadas J; Teng NNH Bioorg Med Chem; 2015 Aug; 23(15):4576-4582. PubMed ID: 26164623 [TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells. Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278 [TBL] [Abstract][Full Text] [Related]
10. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines. Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688 [TBL] [Abstract][Full Text] [Related]
11. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma. Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371 [TBL] [Abstract][Full Text] [Related]
12. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137 [TBL] [Abstract][Full Text] [Related]
13. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids. Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799 [TBL] [Abstract][Full Text] [Related]
14. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Kwok JM; Peck B; Monteiro LJ; Schwenen HD; Millour J; Coombes RC; Myatt SS; Lam EW Mol Cancer Res; 2010 Jan; 8(1):24-34. PubMed ID: 20068070 [TBL] [Abstract][Full Text] [Related]
15. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012 [TBL] [Abstract][Full Text] [Related]
16. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells. Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723 [TBL] [Abstract][Full Text] [Related]
17. Increased FOXM1 Expression by Cisplatin Inhibits Paclitaxel-Related Apoptosis in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma (OSCC) Cell Lines. Choi HS; Kim YK; Hwang KG; Yun PY Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255409 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer. Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy. Lin J; Zheng Y; Chen K; Huang Z; Wu X; Zhang N Oncol Rep; 2013 Oct; 30(4):1739-44. PubMed ID: 23912794 [TBL] [Abstract][Full Text] [Related]
20. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. Parashar D; Nair B; Geethadevi A; George J; Nair A; Tsaih SW; Kadamberi IP; Gopinadhan Nair GK; Lu Y; Ramchandran R; Uyar DS; Rader JS; Ram PT; Mills GB; Pradeep S; Chaluvally-Raghavan P Cancer Res; 2020 Dec; 80(24):5554-5568. PubMed ID: 33087324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]